Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Geminin coiled-coil domain-containing protein 1 (GMNC)
- Target
- GMNC
- Molecular classification
- Transcription factor (promotes cell-type-specific gene activation), Chromatin-binding protein (geminin family), Cell cycle protein, Other (regulator of ciliogenesis and DNA-replication licensing)
01
Overview
Geminin coiled-coil domain-containing protein 1 is a member of the Geminin family of chromatin-binding proteins, encoded by GMNC on chromosome 3q28. It is a transcriptional regulator essential for the differentiation of multiciliated cells in diverse tissues, including the respiratory tract, brain, and reproductive system. GMNC/GEMC1 acts by activating transcriptional programs for multiciliogenesis, promoting expression of key regulators such as MCIDAS, FOXJ1, TP73, CCNO, and others that drive MCC fate and ciliogenesis. GMNC also interacts with proteins like E2F4/5-DP1, Multicilin (MCIDAS), and Geminin through its coiled-coil and TIRT domains, forming complexes that orchestrate gene activation during multiciliogenesis. Deficiency or mutation in GMNC/GEMC1 impairs MCC development and leads to ciliopathies such as Reduced Generation of Multiple Motile Cilia (RGMC), hydrocephalus, chronic airway mucus accumulation, and reproductive system infertility. There is no evidence that GMNC/GEMC1 is currently used as a therapeutic drug target or biomarker in clinical practice.
- Other names
- GEMC1GMNCGeminin coiled-coil domain-containing protein 1GemC1
02
Biological functions
Cell cycle regulationInitiation of DNA replicationMulticiliated cell (MCC) differentiationCilium assemblyCell population proliferationTranscriptional regulation of multiciliogenesis-specific programs
03
Disease associations
Ciliopathy (Reduced Generation of Multiple Motile Cilia, RGMC)HydrocephalusRespiratory mucociliary clearance disordersInfertility (male and female, related to impaired MCC development in reproductive tracts)Growth disorders (due to MCC defects)Other (potential role in cancer, based on expression patterns but not well-defined as therapeutic target)
04
Safety considerations
No known therapeutic safety concerns (not a current drug target)Pathogenic loss of GMNC function causes diseases (e.g., hydrocephalus, infertility), not drug-induced toxicities
05
Biomarkers
GMNC/GEMC1 mutations (research biomarker)GMNC/GEMC1 protein levels (research biomarker)
Beyond the preview
Go deeper on Geminin coiled-coil domain-containing protein 1 (GMNC).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Geminin coiled-coil domain-containing protein 1 (GMNC).